Truist raised the firm’s price target on Pacs Group to $44 from $36 and keeps a Buy rating on the shares. The firm is updating its model after the company’s “strong” Q2 earnings beat, also increasing its 2024-2026 adjusted EBITDA estimates to $378M, $472M and $536M vs. prior $356M, $454M and $520M, respectively, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACS: